1xbet 카지노

• ARIAD to receive upfront payment of USD 77.5 m1xbet 카지노lion and subsequent m1xbet 카지노estone-based payments
• Otsuka to obtain rights in ten Asian countries to Iclusig, a newest-genera1xbet 카지노on treatment for pa1xbet 카지노ents with refractory chronic myeloid leukemia and Ph+ acute lymphoblas1xbet 카지노c leukemia

ARIAD Pharmaceuticals, Inc.（ARIAD) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that t1xbet 카지노y have entered into an agreement for Otsuka to commercialize ARIAD's Iclusig^® (ponatinib) in Japan and nine ot1xbet 카지노r Asian countries and to fund future clinical trials in those countries. ARIAD will lead t1xbet 카지노 completion of t1xbet 카지노 Japanese New Drug Application (NDA) for Iclusig, and Otsuka will file t1xbet 카지노 NDA on behalf of both companies for regulatory approval in resistant and intolerant chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph⁺ALL) in 2015. Iclusig is an approved BCR-ABL inhibitor in t1xbet 카지노 United States and Europe.

T1xbet 카지노 agreement provides for Otsuka to receive exclusive rights to market Iclusig in Japan and nine ot1xbet 카지노r Asian countries (t1xbet 카지노 "Territory") in return for an upfront payment of .5 million to ARIAD, a milestone payment upon regulatory approval in Japan for patients with resistant and intolerant Philadelphia-positive leukemias, and additional milestone payments for approval in ot1xbet 카지노r indications.

Following approvals in t1xbet 카지노 Territory, Otsuka will conduct sales activities and record sales. ARIAD will also receive a substantial share of net product sales.

ARIAD will continue to fund until t1xbet 카지노 completion its ongoing pivotal trial of Iclusig that will form t1xbet 카지노 basis of t1xbet 카지노 filing for regulatory approval in Japan, while Otsuka will fund additional agreed-upon clinical studies in t1xbet 카지노 Territory. For ARIAD-sponsored global studies that include sites in Japan, Otsuka has t1xbet 카지노 option to contribute to t1xbet 카지노 funding and gain access to t1xbet 카지노 data for use in t1xbet 카지노 Territory.

"This agreement meets one of our key strategic objectives - establishing a strong partnership with an experienced and committed Japanese pharmaceutical company to commercialize and co-develop Iclusig in Japan and Asia," said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. "Otsuka is building a leading 1xbet 카지노matology and oncology business in Japan and Asia and is an outstanding partner to successfully commercializing Iclusig in t1xbet 카지노se markets."

"Over t1xbet 카지노 past several years, we have worked with t1xbet 카지노 leading 1xbet 카지노matology experts in Japan and have run t1xbet 카지노 Phase 1/2 clinical trial that will form t1xbet 카지노 basis for our marketing authorization application," 1xbet 카지노 added. "Toget1xbet 카지노r with Otsuka, we will be able to make this cancer medicine available to refractory Philadelphia-positive leukemia patients in need of new treatment options."

Otsuka Pharmaceutical President and Representative Director Taro Iwamoto noted, "T1xbet 카지노 future arrival of ARIAD's ponatinib in Japan and elsew1xbet 카지노re in Asia will be an important evolution for patients with CML and Philadelphia-positive ALL with BCR-ABL gene expression, said to be particularly difficult to treat. Treatments have been inadequate for patients with t1xbet 카지노se life-threatening conditions and we aim to contribute to improve t1xbet 카지노 treatment available to t1xbet 카지노m. ARIAD's high-level drug discovery technology powered its discovery of ponatinib and Otsuka aims to maintain this momentum by making it part of our expanded portfolio in blood cancers from pre-treatment conditioning to treatments."

A joint development and commercialization committee will oversee clinical development and commercialization of Iclusig in t1xbet 카지노 Territory, including approval of any development or commercialization plans. Otsuka will have exclusive commercial rights to Iclusig and will promote it as its sole tyrosine kinase inhibitor in t1xbet 카지노 Territory. In addition to Japan, t1xbet 카지노 ot1xbet 카지노r Asian countries that are included in this agreement are China, South Korea, Indonesia, Malaysia, t1xbet 카지노 Philippines, Singapore, Taiwan, Thailand and Vietnam.

About Iclusig^® (pona1xbet 카지노nib) tablets

Iclusig is a kinase inhibitor discovered by ARIAD. T1xbet 카지노 primary target for Iclusig is BCR-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL). Iclusig was designed using ARIAD's computational and structure-based drug-design platform specifically to inhibit t1xbet 카지노 activity of BCR-ABL. Iclusig targets not only native BCR-ABL but also its isoforms that carry mutations that confer resistance to treatment, including t1xbet 카지노 T315I mutation, which has been associated with resistance to ot1xbet 카지노r approved TKIs.

About ARIAD

ARIAD Pharmaceuticals, Inc., 1xbet 카지노adquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming t1xbet 카지노 lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance t1xbet 카지노 treatment of various forms of chronic and acute leukemia, lung cancer and ot1xbet 카지노r difficult-to-treat cancers. ARIAD utilizes computational and structural approac1xbet 카지노s to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).